RoccaMAPreziosaPBarkhofF, et al. Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. Lancet Reg Health Eur2024; 44: 100978.
2.
KhalilMTeunissenCELehmannS, et al. Neurofilaments as biomarkers in neurological disorders – Towards clinical application. Nat Rev Neurol2024; 20(5): 269–287.
3.
FreedmanMSGnanapavanSBoothRA, et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. Ebiomedicine2024; 101: 104970.
4.
BenkertPMeierSSchaedelinS, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol2022; 21(3): 246–257.
5.
ZiemssenTFreedmanMSBar-OrA, et al. Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis. Mult Scler2025; 31(13): 1543–1556.
6.
EinsiedlerMMaceskiAMSandgrenS, et al. Serum neurofilament light chain in multiple sclerosis: Superiority of age- and BMI-corrected Z Scores/Percentiles over absolute cutoff values for prediction of treatment response. Ann Clin Transl Neurol2025; 12(11): 2214–2225.
7.
Bar-OrAJiaXThaneiG, et al. Poster: Deriving an NfL threshold equivalent from Atellica® to Simoa® assays in ocrelizumab phase 3 trials to assess disease activity risk in RMS. ACTRIMS FORUM 2025 Mult Scler 2025; 31: 24–244.
8.
LeppertDKropshoferHHäringDA, et al. Blood neurofilament light in progressive multiple sclerosis: Post Hoc analysis of 2 randomized controlled trials. Neurology2022; 98: e2120–e2131.
9.
Bar-OrAThaneiGAHarpC, et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: Findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. Ebiomedicine2023; 93: 104662.
10.
KuhleJKropshoferHHaeringDA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology2019; 92: e1007–e1015.
